The FDA granted its Breakthrough Designation to expedite development and review of Johnson & Johnson’s TAR-200 implant. Originally developed in the Cima Lab to make treating bladder cancer safer, more effective and less costly, the device is currently in clinical trials to replace standard regimens with continuously administered gemcitabine in the bladder.